Characteristics of evaluable allogeneic HCT study patients
| Characteristic . | Immunized donor group, n = 30 . | Unimmunized donor group, n = 35 . |
|---|---|---|
| Median age, y (range) | ||
| Recipient | 41 (2-59) | 39 (4-64) |
| Donor | 42 (4-63) | 39 (3-66) |
| White race/other | 28/2 | 33/2 |
| Male/female | 13/17 | 22/13 |
| Diagnosis | ||
| Myelodysplastic syndrome (%) | 3 (10) | 5 (14) |
| Leukemia (%) | 21 (70) | 28 (80) |
| Aplastic anemia (%) | 4 (13) | 2 (6) |
| Lymphoma (%) | 2 (7) | 0 (0) |
| Total body irradiation (%) | 25 (83) | 31 (89) |
| No. with GVHD/no. evaluable*(%) | ||
| 3 mo | 6/30 (20) | 5/35 (14) |
| 6 mo | 2/24 (8) | 6/29 (21) |
| 12 mo | 2/20 (10) | 5/26 (19) |
| No. who received IVIG†/no. evaluable (%) | ||
| 3 mo | 6/30 (20) | 9/35 (26) |
| 6 mo | 2/24 (8) | 2/29 (7) |
| 12 mo | 1/20 (5) | 1/26 (4) |
| Geometric mean concentration of serum antibody of donors at harvest, μg/mL | ||
| Pneumococcal serotype | ||
| 4 | 2.48 | 0.94‡ |
| 6B | 3.87 | 1.05‡ |
| 9V | 3.49 | 1.18‡ |
| 14 | 8.94 | 1.52‡ |
| 18C | 3.68 | 1.10‡ |
| 19F | 4.99 | 2.831-153 |
| 23F | 4.31 | 0.71‡ |
| Characteristic . | Immunized donor group, n = 30 . | Unimmunized donor group, n = 35 . |
|---|---|---|
| Median age, y (range) | ||
| Recipient | 41 (2-59) | 39 (4-64) |
| Donor | 42 (4-63) | 39 (3-66) |
| White race/other | 28/2 | 33/2 |
| Male/female | 13/17 | 22/13 |
| Diagnosis | ||
| Myelodysplastic syndrome (%) | 3 (10) | 5 (14) |
| Leukemia (%) | 21 (70) | 28 (80) |
| Aplastic anemia (%) | 4 (13) | 2 (6) |
| Lymphoma (%) | 2 (7) | 0 (0) |
| Total body irradiation (%) | 25 (83) | 31 (89) |
| No. with GVHD/no. evaluable*(%) | ||
| 3 mo | 6/30 (20) | 5/35 (14) |
| 6 mo | 2/24 (8) | 6/29 (21) |
| 12 mo | 2/20 (10) | 5/26 (19) |
| No. who received IVIG†/no. evaluable (%) | ||
| 3 mo | 6/30 (20) | 9/35 (26) |
| 6 mo | 2/24 (8) | 2/29 (7) |
| 12 mo | 1/20 (5) | 1/26 (4) |
| Geometric mean concentration of serum antibody of donors at harvest, μg/mL | ||
| Pneumococcal serotype | ||
| 4 | 2.48 | 0.94‡ |
| 6B | 3.87 | 1.05‡ |
| 9V | 3.49 | 1.18‡ |
| 14 | 8.94 | 1.52‡ |
| 18C | 3.68 | 1.10‡ |
| 19F | 4.99 | 2.831-153 |
| 23F | 4.31 | 0.71‡ |
Of the 30 patients in the immunized donor group, 6 dropped out of the study between 3 and 6 months (2 died, 2 relapsed, 1 missed immunization, and 1 had refractory thrombocytopenia). Four additional patients dropped out between 6 and 12 months (1 died, 2 relapsed, 1 received donor lymphocyte infusions). Of the 35 patients in the unimmunized donor group, 6 dropped out between 3 and 6 months (1 died, 3 relapsed, 1 had severe thrombocytopenia, 1 had persistent pancytopenia). Three more patients dropped out of the study between 6 and 12 months (1 died, 1 relapsed, 1 missed immunization).
Administered within 30 days of immunization.
P ≤ .002 by t test comparing immunized donors to unimmunized donors.
P = .048 by t test comparing immunized donors to unimmunized donors.